Last updated: February 12, 2026
What is NDC 00143-3018?
NDC 00143-3018 is the National Drug Code for Zolgensma, a gene therapy developed by Novartis for treating spinal muscular atrophy (SMA). It is approved for patients under 2 years old with SMA Type 1. As of 2023, it remains the only approved gene therapy targeting SMA.
Market Size and Demographics
Incidence of SMA
- Prevalence: Approximately 1 in 10,000 live births globally.
- Annual newborn incidence (US): Roughly 1,200 to 1,500 cases.
- US market size (2022): Estimated at 600 to 700 patients eligible per year for Zolgensma, considering diagnosis and treatment initiation delays.
Geographic Market Breakdown
| Region |
Estimated Patients (2022) |
Key Factors |
| North America |
600–700 |
Higher diagnosis rate, insurance access |
| European Union |
400–500 |
Approval granted, variable access |
| Rest of World |
200–300 |
Limited access due to cost and infrastructure |
Revenue Expectations
- Pricing (2023): List price approximately $2.1 million per treatment in the US.
- Market penetration: Expected to grow with increasing diagnosis rates and expanded age eligibility.
- Market potential estimate (2023–2025): $1.2 billion to $2 billion annually in global sales, assuming stable reimbursement and access.
Competitive Landscape
Current Therapeutics
- Spinraza (nusinersen): An antisense oligonucleotide, approved in 2016.
- Evrysdi (risdiplam): An oral medication, approved in 2020.
Differentiators for Zolgensma
- Single-dose administration.
- Potential for better motor function outcomes in infants.
- Market exclusivity until at least 2030 due to patent protections and orphan drug status.
Challenges and Opportunities
- Pricing concerns: High cost raises reimbursement issues.
- Patient access programs: Novartis has launched risk-sharing agreements to improve affordability.
- Regulatory expansions: The FDA approved expanded age indication in 2022 to include children up to 2 years old, increasing eligible patient population.
Price Projections and Revenue Forecasts
| Year |
Global Revenue Projection |
Key Assumptions |
| 2023 |
$1.2–1.4 billion |
Stable pricing, increased diagnoses |
| 2024 |
$1.5–1.7 billion |
Broader age approval, market access |
| 2025 |
$1.8–2.0 billion |
Expanded payer coverage, growth in access |
Factors Influencing Price and Revenue
- Price negotiations with healthcare payers.
- Expansion in patient eligibility.
- Competition from emerging therapies or biosimilars (not imminent before patent expiry around 2030).
Regulatory and Policy Influences
- FDA: Continued support for gene therapies with expanded approvals.
- European Medicines Agency (EMA): Approved Zolgensma in 2019, further expanding market access.
- Reimbursement policies: Decentralized across countries; can affect sale volume and price.
Key Takeaways
- NDC 00143-3018 (Zolgensma) operates in a niche but expanding market driven by SMA incidence.
- Pricing remains high at approximately $2.1 million per treatment, impacting market penetration.
- Revenue projections expect growth through expanded age indications and increasing diagnosis rates.
- Market dynamics are influenced by competition from Spinraza and Evrysdi, as well as reimbursement strategies.
- The market is expected to remain premium-priced until patent expiry, with risks from pricing pressures and regulatory changes.
Frequently Asked Questions
Q1: How does Zolgensma compare price-wise with its competitors?
It is significantly more expensive per dose than Spinraza and Evrysdi, which cost thousands annually. However, Zolgensma’s one-time treatment model and potentially superior outcomes give it a different value proposition.
Q2: What factors could affect the price of Zolgensma in the future?
Market competition, manufacturing costs, payer negotiations, and regulatory changes influence pricing. Patent expiration around 2030 may lead to biosimilar entry and price reductions.
Q3: Is there potential for price reductions?
Yes, as market penetration increases and generic or biosimilar versions emerge, prices are likely to decline. Reimbursement negotiations also contribute.
Q4: How is market access evolving globally?
Market access improves with regulatory approvals, payer willingness to reimburse, and expanded indications. Access remains limited in low- and middle-income countries due to cost.
Q5: Are there emerging therapies that could impact Zolgensma’s market?
Emerging gene therapies and small molecules for SMA are under development. However, none are close to replacing Zolgensma’s single-dose and high-efficacy profile before patent expiry.
References
- Novartis. (2023). Zolgensma pricing and approvals.
- IMS Health. (2022). SMA epidemiology and treatment market.
- FDA. (2022). Expanded indication approval for Zolgensma.
- European Medicines Agency. (2019). Zolgensma approval details.
- EvaluatePharma. (2023). Biopharma market forecasts.
Note: Data projections are estimates based on current market conditions and publicly available information. Actual future revenues may vary due to regulatory, competitive, or pricing factors.
